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Introduction
Zymosan, a yeast-derived β-glucan-and mannan-rich particle (Brown et al., 2010) , has been shown to markedly reduce the phagocytic activity of DCs (Reis e Sousa et al., 1993) , to inhibit production of specific pro-inflammatory molecules such as TNF-α, and to induce high levels of IL-10 production by macrophages and DCs (Saijo et al., 2003; Samarasinghe et al., 2006; Goodridge et al., 2007; Slack et al., 2007) . MHC class II expression is central to immune regulation in T-cell-mediated autoimmune disease (Steinman et al., 1980 (Steinman et al., , 1981 Bottazzo et al., 1983; Slavin et al., 2001) . Zymosan prevented IFN-γ-inducible MHC class II expression on monocytes (Volk et al., 1986) , suggesting that zymosan might inhibit antigen presentation to pro-inflammatory Th cells (Volk et al., 1986) . In the Volk et al. study, it was observed that following digestion of phagocytosed zymosan particles, IFN-γ could not restore MHC class II antigen expression on cultured monocytes, suggesting that soluble yeast β-glucan may work in a different way than whole yeast β-glucan particles (WGPs) (Volk et al., 1986) . Although resident macrophages were effectively activated by WGPs, the binding ability of WGPs and the levels of cytokine secretion in resident macrophages were significantly inhibited by soluble yeast β-glucan, but not by blockade of the zymosan glucan receptor dectin-1. These observations suggest that β-glucan recognition is necessary but in itself not sufficient to induce the inflammatory response of resident macrophages. In addition, soluble yeast β-glucan may use differential mechanisms for cytokine secretion in resident macrophages that may modulate both innate and adaptive immunity (Li et al., 2007) .
Recent studies have shown that zymosan signaling via the TLR2 and dectin-1 pathway can regulate cytokine secretion by CD11c + CD11b + DCs and macrophages to induce immune tolerance (Dillon et al., 2006; Slack et al., 2007) . These observations suggest that zymosan could be beneficial in MS. In this study, we examined the effect of zymosan on triggering of regulatory APCs and T cells, induction of immune tolerance, and amelioration and reversal of paralysis in the EAE model.
Materials and methods

Animals
Female SJL/J and C57BL/6 mice (8-12 weeks old) were purchased from the Jackson Laboratory (Bar Harbor, ME). MOG-specific T-cell receptor transgenic mice (2D2) were a generous gift from Dr. Vijay K. Kuchroo, (Harvard University). All mice were housed in Thomas Jefferson University animal care facilities. All work was performed in accordance with the Thomas Jefferson University guidelines for animal use and care. Mouse MOG 35-55 peptide (MEVGWYRSPFSRVVHLYRNGK) and PLP 139-151 peptide (HCLGKWLGHPDKF) were purchased from Invitrogen (Carlsbad, CA).
